Showing results (571-580 of 646) with videos related to

Sort By:
Pageof 65
Journal of Virology|February 6, 2015
Dynamics of the cytotoxic T cell response to a model of acute viral infectionWilliam S DeWitt, Ryan O Emerson, Paul Lindau, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 8, 2025
Ibrutinib and Venetoclax in Relapsed and Refractory Follicular LymphomaChaitra Ujjani, Hongkun Wang, Catherine Broome, et al.
Environmental Health Perspectives|January 27, 2018
Mutagenicity and Lung Toxicity of Smoldering vs. Flaming Emissions from Various Biomass Fuels: Implications for Health Effects from Wildland FiresYong Ho Kim, Sarah H Warren, Q Todd Krantz, et al.
British Journal of Haematology|October 10, 2025
Long-term follow-up of dose-dense brentuximab vedotin, ifosfamide, carboplatin and etoposide in second-line treatment of relapsed/refractory classical Hodgkin lymphomaRyan C Lynch, Ryan D Cassaday, Stephen D Smith, et al.
JCO Global Oncology|April 4, 2025
Phase I Study of Subcutaneous Rituximab Hyaluronidase Combined With CHOP Chemotherapy for the Treatment of Diffuse Large B-Cell Lymphoma in UgandaManoj P Menon, Henry Ddungu, Kelvin R Mubiru, et al.
The Annals of Thoracic Surgery|September 28, 2011
Biomarkers of the insulin-like growth factor pathway predict progression and outcome in lung cancerDavid D Shersher, Michael S Vercillo, Cristina Fhied, et al.
Science (New York, N.Y.)|September 9, 2006
An antigen produced by splicing of noncontiguous peptides in the reverse orderEdus H Warren, Nathalie J Vigneron, Marc A Gavin, et al.
Blood|April 25, 2012
Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigenSebastian Ochsenreither, Ravindra Majeti, Thomas Schmitt, et al.
Environmental and Molecular Mutagenesis|April 4, 2017
Mutagenicity and oxidative damage induced by an organic extract of the particulate emissions from a simulation of the deepwater horizon surface oil burnsDavid M DeMarini, Sarah H Warren, Katelyn Lavrich, et al.
American Journal of Hematology|June 17, 2026
Outcomes From the Multicenter ACCRU-LY-1804/CARiBOU TRIAL (Cytarabine, Acalabrutinib and Rituximab Integrated With Bortezomib-Based Outpatient Therapy) in 1st Line Mantle Cell LymphomaStephen D Smith, Suchitra Sundaram, Sharmila Giri, et al.
Pageof 65